Get started
Author

Karin M Abernathy

Observed names: K. Abernathy, Karin Abernathy
ORCID: 0000-0002-5669-1803
Observed ORCID: 0000-0002-5669-1803
OpenAlex ID: A5071013667
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
2024 · Katie Gatwood, Zahra Mahmoudjafari, et al. · Clinical Hematology International · 27
PDF
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma
2025 · Uttam K. Rao, Navneet S. Majhail, et al. · Transplantation and Cellular Therapy · 11
Real-world analysis of tumor lysis syndrome in patients started on venetoclax combination for acute myeloid leukemia
2022 · Karin M Abernathy, Matthew A Perciavalle, et al. · Journal of Oncology Pharmacy Practice · 10
Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase
2025 · Joseph F. Mort, David Brighton, et al. · Blood Vessels Thrombosis & Hemostasis · 3
Efficacy and safety of outpatient fludarabine, cyclophosphamide, and rituximab based allogeneic hematopoietic cell transplantation in adults with severe aplastic anemia
2024 · Rachel M. Gilmore, Karin Abernathy, et al. · Bone Marrow Transplantation · 2
Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia
2022 · Rachel M Gilmore, Karin M Abernathy, et al. · Blood · 1
P354: Real-world Analysis of the Risks of Thrombotic and Bleeding Events in Patients Receiving Pegylated Asparaginase for Treatment of Acute Lymphoblastic Leukemia
2022 · B. Mautner, B. Brewer, et al. · HemaSphere
P526: Real-world Comparison of Different Treatment Modalities for Favorable Risk Acute Myeloid Leukemia: Standard Dose Anthracycline Vs High Dose Anthracycline Vs Addition of Gemtuzumab Ozogamicin
2022 · J. Mort, B. Brewer, et al. · HemaSphere
Evaluation of formulation-associated ifosfamide neurotoxicity.
2022 · Karin Abernathy, Colleen McCabe, et al. · Journal of Clinical Oncology
Works count: 9
Citation count: 54
H-index: 3
I10-index: 3
Year
Topic
Type